Follicular Histotypes of Oncocytic Thyroid Carcinomas Do Not Carry Mutations of the <i>BRAF</i> Hot‐spot

Musholt, Petra B.; Musholt, Thomas J.; Morgenstern, Saskia C.; Worm, Karl; Sheu, Sien‐Yi; Schmid, Kurt Werner

doi:10.1007/s00268-007-9431-6

Cited by 24 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike papillary thyroid carcinomas, which often have BRAF activating mutations or RET/PTC gene rearrangements, these molecular alterations are either not associated with Hürthle cell tumors (23,24) or are only seen in a minority of cases (25). Similarly, while RAS mutations and PAX8/PPARc gene rearrangements most often characterize follicular carcinomas, a minority of Hürthle cell tumors harbor such genetic changes (24-27).…”

Section: Discussionmentioning

confidence: 99%

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules

Brauner

Holmes

Krane

et al. 2015

Thyroid

112

128

View full text Add to dashboard Cite

While 32% of tested patients declined surgery based on a benign AGEC, 86% of patients with suspicious AGEC findings had unnecessary surgery, reflecting a substantially lower rate of malignancy from what was previously reported for all indeterminate nodules. Given the approximate pretest malignancy risk of 25-35% for an FNA diagnosis of SHCN or AFHCN, a suspicious AGEC diagnosis does not increase the probability of malignancy in an HCN, and patients should be counseled accordingly.

show abstract

Section: Discussionmentioning

confidence: 99%

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules

Brauner

Holmes

Krane

et al. 2015

Thyroid

112

128

View full text Add to dashboard Cite

show abstract

“…In Hürthle-cell thyroid carcinoma (HCTC), mutations of NADH dehydrogenase (ubiquinone) 1α subcomplex 13 ( NDUFA13 ; also known as GRIM19 ) are fairly common 45 . Unlike other types of thyroid cancers, HCTC does not harbour classical genetic alterations, such as BRAF and RAS mutations or RET– PTC 46,47 , but commonly harbours DNA haploidization in recurrent disease 47 .…”

Section: Common Genetic Alterations In Thyroid Cancermentioning

confidence: 99%

Molecular pathogenesis and mechanisms of thyroid cancer

2013

View full text Add to dashboard Cite

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in understanding its molecular pathogenesis in recent years, as best exemplified by the elucidation of the fundamental role of several major signalling pathways and related molecular derangements. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation, gene copy-number gain and aberrant gene methylation. Many of these molecular alterations represent novel diagnostic and prognostic molecular markers and therapeutic targets for thyroid cancer, which provide unprecedented opportunities for further research and clinical development of novel treatment strategies for this cancer.

show abstract

“…Interestingly, B-Raf mutations also present in some follicular variants of PTC tumors (~12%), but they have not been seen in any of the oncocytic PTCs. 18 …”

Section: Clinicopathological Correlationmentioning

confidence: 99%

Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules

Mekel

Nucera

Hodin

et al. 2010

The American Journal of Surgery

View full text Add to dashboard Cite

BACKGROUND Management of patients with thyroid nodules is based on establishing an accurate diagnosis; however, differentiating benign from malignant lesions preoperatively is not always possible using current cytological techniques. Novel molecular testing on cytological material could lead to clearer treatment algorithms. B-RafV600E mutation is the most common genetic alteration in thyroid cancer, specifically found in papillary thyroid cancer (PTC), and usually reported to be associated with aggressive disease. DATA SOURCE A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-RafV600E mutation in thyroid cancer. CONCLUSIONS The utility of using B-Raf mutation testing for nodules with indeterminate cytology is limited since many of those nodules (benign and malignant) do not harbor B-Raf mutations. However, when the pathologist sees cytological features suspicious for PTC, B-RafV600E mutation analysis may enhance the assessment of preoperative risks for PTC, directing a more aggressive initial surgical management when appropriate.

show abstract

Follicular Histotypes of Oncocytic Thyroid Carcinomas Do Not Carry Mutations of the BRAF Hot‐spot

Cited by 24 publications

References 45 publications

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules

Molecular pathogenesis and mechanisms of thyroid cancer

Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules

Contact Info

Product

Resources

About